BioCryst Pharmaceuticals, Inc.

DB:BO1 Stock Report

Market Cap: €2.0b

BioCryst Pharmaceuticals Management

Management criteria checks 2/4

BioCryst Pharmaceuticals' CEO is Jon Stonehouse, appointed in Jan 2007, has a tenure of 18.42 years. total yearly compensation is $8.32M, comprised of 8.5% salary and 91.5% bonuses, including company stock and options. directly owns 0.45% of the company’s shares, worth €8.90M. The average tenure of the management team and the board of directors is 4.8 years and 5.3 years respectively.

Key information

Jon Stonehouse

Chief executive officer

US$8.3m

Total compensation

CEO salary percentage8.48%
CEO tenure18.4yrs
CEO ownership0.4%
Management average tenure4.8yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jon Stonehouse's remuneration changed compared to BioCryst Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$53m

Dec 31 2024US$8mUS$706k

-US$89m

Sep 30 2024n/an/a

-US$124m

Jun 30 2024n/an/a

-US$146m

Mar 31 2024n/an/a

-US$209m

Dec 31 2023US$5mUS$666k

-US$227m

Sep 30 2023n/an/a

-US$236m

Jun 30 2023n/an/a

-US$243m

Mar 31 2023n/an/a

-US$226m

Dec 31 2022US$7mUS$640k

-US$247m

Sep 30 2022n/an/a

-US$193m

Jun 30 2022n/an/a

-US$210m

Mar 31 2022n/an/a

-US$194m

Dec 31 2021US$7mUS$583k

-US$184m

Sep 30 2021n/an/a

-US$227m

Jun 30 2021n/an/a

-US$214m

Mar 31 2021n/an/a

-US$209m

Dec 31 2020US$6mUS$567k

-US$183m

Sep 30 2020n/an/a

-US$125m

Jun 30 2020n/an/a

-US$116m

Mar 31 2020n/an/a

-US$115m

Dec 31 2019US$2mUS$550k

-US$109m

Sep 30 2019n/an/a

-US$134m

Jun 30 2019n/an/a

-US$126m

Mar 31 2019n/an/a

-US$107m

Dec 31 2018US$4mUS$550k

-US$101m

Compensation vs Market: Jon's total compensation ($USD8.32M) is above average for companies of similar size in the German market ($USD1.71M).

Compensation vs Earnings: Jon's compensation has increased whilst the company is unprofitable.

CEO

Jon Stonehouse (64 yo)

18.4yrs
Tenure
US$8,317,286
Compensation

Mr. Jon P. Stonehouse is Director of Metsera, Inc. from April 28, 2025. Mr. Stonehouse has been the Chief Executive Officer and Executive Director of BioCryst Pharmaceuticals, Inc. at Shionogi & Co. Ltd. s...

Leadership Team

NamePositionTenureCompensationOwnership
Jon Stonehouse
CEO, President & Executive Director and Interim CFO18.4yrsUS$8.32m0.45%
€ 8.9m
Alane Barnes
Senior VP18.8yrsUS$3.24m0.10%
€ 2.0m
Helen Thackray
Chief Research & Development Officer4.3yrsUS$3.57m0.077%
€ 1.5m
Charles Gayer
Senior VP & Chief Commercial Officer5.4yrsUS$3.38m0.11%
€ 2.3m
John Bluth
Chief Communications Officerno datano datano data
Stephanie Angelini
Chief People Officerno datano datano data
William Sheridan
Chief Development Officer16.9yrsUS$2.66mno data
Yarlagadda Babu
Chief Discovery Officer11.7yrsUS$2.57mno data
Jinky Rosselli
Chief Data & Insights Officer3.6yrsno datano data
Philip George
Chief Strategy Officer2.8yrsno datano data
Clayton Fletcher
Chief Business Development Officer2.4yrsno datano data
Salisa Hauptmann
Chief Regulatory Officer2yrsno datano data
4.8yrs
Average Tenure
59yo
Average Age

Experienced Management: BO1's management team is considered experienced (4.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jon Stonehouse
CEO, President & Executive Director and Interim CFO18.4yrsUS$8.32m0.45%
€ 8.9m
Vincent Milano
Independent Director3.9yrsUS$347.97k0.033%
€ 662.0k
Stephen Aselage
Independent Director6.4yrsUS$346.72k0.031%
€ 623.3k
Alan Levin
Independent Director5.3yrsUS$342.97k0.021%
€ 425.6k
Steven Frank
Directorless than a yearno datano data
George Abercrombie
Independent Director13.7yrsUS$337.97k0.014%
€ 280.4k
Theresa Heggie
Independent Director6.5yrsUS$342.97k0.022%
€ 435.9k
Nancy Hutson
Independent Chair13.4yrsUS$377.97k0.038%
€ 755.7k
Steven K. Galson
Independent Director3.8yrsUS$330.47k0.025%
€ 488.2k
A. Sanders
Independent Director3.3yrsUS$330.47k0.010%
€ 198.1k
Amy McKee
Independent Director3.8yrsUS$335.47k0.010%
€ 198.9k
5.3yrs
Average Tenure
65yo
Average Age

Experienced Board: BO1's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/01 00:51
End of Day Share Price 2025/05/30 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioCryst Pharmaceuticals, Inc. is covered by 30 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Tazeen AhmadBofA Global Research
Dae Gon HaBTIG